Not exact matches
Katherine High, Spark's president and chief scientific officer, expressed her enthusiasm for the early clinical data related to SPK - 8011: «The encouraging start of our SPK - 8011 clinical trial reinforces the strength of our
gene therapy platform, delivers human proof - of - concept in a second liver - mediated disease — a significant achievement in the
gene therapy field — and positions us well to potentially transform the
current treatment
approach for this life - altering disease with a one - time intervention.»
Kohn's
gene therapy approach using HSC from patient's own blood is a revolutionary alternative to
current SCD treatments as it creates a self - renewing normal blood cell by inserting a
gene that has anti-sickling properties into HSC.
The finding, published in the
current issue of
Genes and Development1 represents a different
approach to cultivating specialized cells for transplant
therapy than that being pursued in other labs.
Current precision medicine
approaches aim to disable those mutated
genes, and many cancer patients today have their tumors analyzed for mutated
genes that can be treated with available targeted
therapies.
His
gene therapy — delivering nanoparticles could transform patients into their own T - cell engineering labs, allowing them to be treated with reprogrammed T cells almost from the moment of diagnosis, skipping the waiting period and high cost of
current approaches.
Many of the
current cancer researchers are investigating ways of stimulating the immune system to recognize the cancer cells specifically and selectively, for example by a vaccine
approach (See also «
Gene Therapy» below).